K. Rajender Reddy
Hospital of the University of Pennsylvania · 890 works · 68,909 citations · h-index 119
Top works
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- Efficacy and Safety of Pegylated (40–Kd) Interferon α–2A Compared With Interferon α–2A in Noncirrhotic Patients With Chronic Hepatitis C
- Diagnosis and Treatment of Hepatocellular Carcinoma
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
- Hepatitis C-associated hepatocellular carcinoma
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
- American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.